At present the trial protocols do not imply on/off or staggered dosing schedule experiments.
That means some trial patients will not reach their assigned target, but something less.
As we know A2-73 blood concentration is the most important factor of response.
Still I believe there is a very good chance of the overall stat sig results we are looking for probably in fewer patients than many think.
My working assumption is that around 25% of dose arm patients are stable and some proportion of them improve. The rest decline less than SOC and a few likely faster over the same period.
That could potentially be optimised outside the trials and could possibly be part of the OLE e.g. by the kind of dosing schedules disclose in Anavex patents.
If so that would help labelling discussions if A2-73 is approved.
25%, or more due to dosing scheme optimisation, being stable or improve would be a fantastic result.
We should know late next year as far as AD is concerned.
Market Data 
Markets 
AI
